The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia.
Public Health
; 205: 182-186, 2022 Apr.
Article
in English
| MEDLINE | ID: covidwho-1751168
ABSTRACT
OBJECTIVES:
In 2015, the Republic of Georgia initiated a National Hepatitis C Elimination Program, with a goal of 90% reduction in prevalence of chronic hepatitis C virus (HCV) infections by 2020. In this article, we explore the impact of the COVID-19 pandemic on the 2020 hepatitis C cascade of care in Georgia. STUDYDESIGN:
Retrospective analytic study.METHODS:
We used a national screening registry that includes hospitals, blood banks, antenatal clinics, harm reduction sites, and other programs and services to collect data on hepatitis C screening. A separate national treatment database was used to collect data on viremia and diagnostic testing, treatment initiation, and outcome including testing for and achieving sustained virologic response (SVR). We used these databases to create hepatitis C care cascades for 2020 and 2019. Bivariate associations for demographic characteristics and screening locations per year and care cascade comparisons were assessed using a chi-squared test.RESULTS:
In 2020 compared to 2019, the total number of persons screened for HCV antibodies decreased by 25% (from 975,416 to 726,735), 59% fewer people with viremic infection were treated for HCV infection (3188 vs. 7868), 46% fewer achieved SVR (1345 vs. 2495), a significantly smaller percentage of persons with viremic infection initiated treatment for HCV (59% vs. 62%), while the percentage of persons who achieved SVR (99.2% vs. 99.3%) remained stable.CONCLUSIONS:
The COVID-19 pandemic had a negative impact on the hepatitis C elimination program in Georgia. To ensure Georgia reaches its elimination goals, mitigating unintended consequences of delayed diagnosis and treatment of hepatitis C due to the COVID-19 pandemic are paramount.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hepatitis C
/
Hepatitis C, Chronic
/
COVID-19
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Female
/
Humans
/
Pregnancy
Country/Region as subject:
North America
/
Europa
Language:
English
Journal:
Public Health
Year:
2022
Document Type:
Article
Affiliation country:
J.puhe.2022.01.040
Similar
MEDLINE
...
LILACS
LIS